Bunkerhill raises $55M to scale agentic AI across health systems

The healthcare artificial intelligence ecosystem has received a new boost with the recent capital injection from Bunkerhill Health, which closed a Series B round of $55 million to scale its agentic AI platform, Carebricks. The news, backed by investors such as Sequoia Capital, Felicis, Optum Ventures, Y Combinator, and Khosla Ventures, highlights a critical trend: the gap between AI models that work in controlled environments and those capable of operating in real hospitals with live clinical data. This challenge has traditionally limited the adoption of artificial intelligence in the healthcare sector, where numerous promising pilots never touch a patient's medical record. Bunkerhill aims to close that gap with a platform that allows hospitals to build their own agents instead of buying off-the-shelf solutions. The opportunity is immense: healthcare spending in the United States reached $5.3 trillion in 2024, while labor shortages continue to strain institutions. Bunkerhill's proposal focuses on automating clinical and administrative tasks that professionals already want to perform, from reviewing cardiology images to managing prior authorizations. Cleveland Clinic, the University of Texas Medical Branch (UTMB), and Intermountain Health already use the platform. UTMB, for example, has over 20 agents in operation, with results such as early detection of a cardiac risk that led to a triple bypass, or a more than 50% reduction in wait times for nephrology consultations. However, implementing AI agents in hospital settings is not without challenges. Governance, liability assignment, and constant monitoring are aspects that hospital boards must evaluate before scaling. Each department that builds its own agent assumes the consequences of its tuning. In this context, having a technology partner with expertise in developing custom software becomes essential. Generic solutions rarely fully adapt to the clinical workflows and interoperability requirements of each institution. This is where companies like Q2BSTUDIO add value: their focus on personalized software, combined with capabilities in AI, cybersecurity, cloud AWS/Azure, and BI/Power BI, enables building systems that not only work in a lab but integrate securely and scalably into a hospital's real infrastructure. Bunkerhill's investment confirms that the market demands modular and adaptable platforms, capable of growing with the changing needs of healthcare organizations. To achieve that level of customization, software companies must master multiple technology disciplines. Cloud implementation, for example, offers elasticity to handle demand spikes, while cybersecurity practices ensure the protection of sensitive data. AI agents, meanwhile, require continuous training with local data and careful integration with hospital information systems. Q2BSTUDIO's experience in creating intelligent agents, as well as developing Power BI dashboards for performance monitoring, aligns with the needs Bunkerhill is addressing. Although the UTMB case demonstrates that remarkable clinical outcomes are possible, extrapolating to other environments requires caution. The reported metrics — such as an 80% reduction in response time for urgent lung nodule cases — reflect specific data and staffing conditions. Nevertheless, the path is set: agentic AI must move from being an experiment to becoming an operational and audited tool. The funding obtained by Bunkerhill will serve to expand Carebricks to new clinical and administrative use cases, while strengthening governance and oversight systems. For software development companies like Q2BSTUDIO, this trend represents an opportunity to collaborate in building the next generation of healthcare solutions. The combination of custom applications, artificial intelligence, cloud, and cybersecurity not only accelerates the adoption of AI in healthcare but ensures that the software actually runs inside a working hospital, which is, after all, the only question that matters.